PHLDA1 downregulation was proved to promote acquisition and maintenance of drugs resistance targeting receptor tyrosine kinase, which might suppress the effect of trastuzumab treatment on ERBB2 amplification cancers [25]. The gene discussed is ERBB2; the disease is cancer.